 The current study includes patients diagnosed with advanced NSCLC or PC or CRC, with pathological confirmation. The inclusion criteria were NSCLC treated with erlotinib alone and PC treated with gemcitabine and erlotinib combination chemotherapy and CRC treated with cetuximab and5-Fluorouracil 5-FUIrinotecanleucovorinLV FOLFIRI, 5-FUOxaliplatinLV FOLFOX and sufficient liver, kidney, and bone marrow function to undergo treatment. All the patients had Grade 2 ERSEs according to the National Cancer Institutes Common Terminology Criteria for Adverse Events NCI-CTCAE v. 4.03. 